Education
About Us
Working with TipRanks
Follow Us
IRLAB Therapeutics AB Class A (DE:6IRA)
FRANKFURT:6IRA
6IRA Stock Chart & Stats
€0.18
-€0.01(-1.25%)
At close: 4:00 PM EST
€0.18
-€0.01(-1.25%)
Day’s Range― - ―
52-Week Range€0.15 - €1.27
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€12.64M
Enterprise Value€54.09M
Total Cash (Recent Filing)€110.13M
Total Debt (Recent Filing)€29.81M
Price to Earnings (P/E)―
Beta-0.16
Next Earnings
May 06, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding84,858,246
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)17.09
Price to Sales (P/S)5.89
P/FCF Ratio-8.48
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue Growth / Pipeline MomentumSustained ~13% TTM revenue growth after a prior step-change suggests durable pipeline or partnering momentum. For a clinical-stage biotech, rising revenue signals progressing partnerships or milestones that can provide recurring non-product cash inflows and validate program advancement over months.
Improved Leverage Reduces Balance-sheet RiskA marked fall in debt-to-equity to ~0.55 materially lowers refinancing and solvency risk versus 2024. This improvement extends runway flexibility for R&D spending, reduces interest burden and supports funding of clinical programs over the medium term without immediate distress.
Partnering-based Business ModelA business model focused on licensing, milestone payments and royalties lets the company monetize R&D without building broad commercial infrastructure. Structurally this reduces fixed-cost scale needs and provides potential non-dilutive cash at defined program milestones over the coming quarters.
Bears Say
Substantial Cash Burn And Negative FCFPersistently negative operating and free cash flow indicate ongoing funding reliance. Even with improvement versus 2024, continued burn makes the company dependent on external financing or milestone receipts, increasing dilution risk and constraining multi-program development plans.
Negative Gross Profit And Large Operating LossesNegative gross profit and sustained operating losses show the business remains far from breakeven. For a development-stage biotech this implies continued capital consumption to fund trials, limiting ability to self-fund growth and weakening bargaining power with partners and investors over time.
Equity Erosion And Deeply Negative ROEMaterial equity decline and deeply negative ROE reflect capital consumption and likely dilution. This undermines long-term shareholder value, makes future equity raises more costly and signals persistent inability to generate positive returns from invested capital absent a material change in operations or milestones.
IRLAB Therapeutics AB Class A News
6IRA FAQ
What was IRLAB Therapeutics AB Class A’s price range in the past 12 months?
IRLAB Therapeutics AB Class A lowest stock price was €0.15 and its highest was €1.27 in the past 12 months.
What is IRLAB Therapeutics AB Class A’s market cap?
IRLAB Therapeutics AB Class A’s market cap is €12.64M.
When is IRLAB Therapeutics AB Class A’s upcoming earnings report date?
IRLAB Therapeutics AB Class A’s upcoming earnings report date is May 06, 2026 which is in 69 days.
How were IRLAB Therapeutics AB Class A’s earnings last quarter?
Currently, no data Available
Is IRLAB Therapeutics AB Class A overvalued?
According to Wall Street analysts IRLAB Therapeutics AB Class A’s price is currently Overvalued.
Does IRLAB Therapeutics AB Class A pay dividends?
IRLAB Therapeutics AB Class A does not currently pay dividends.
What is IRLAB Therapeutics AB Class A’s EPS estimate?
IRLAB Therapeutics AB Class A’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does IRLAB Therapeutics AB Class A have?
IRLAB Therapeutics AB Class A has 84,858,246 shares outstanding.
What happened to IRLAB Therapeutics AB Class A’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of IRLAB Therapeutics AB Class A?
Currently, no hedge funds are holding shares in DE:6IRA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
IRLAB Therapeutics AB Class A
IRLAB Therapeutics AB (publ) develops drugs for the treatment of Parkinson's disease. The company develops Mesdopetam that is in phase IIb/III clinical studies for the treatment of dyskinesia; and Pirepemat, which is in phase IIb clinical trial for the treatment of Postural dysfunction. Its preclinical stage products include IRL942 and 1009 research programs for the treatment of neurodegenerative disorders and ageing; and IRL757 to treat apathy in neurological diseases. In addition, the company develops P003, a research project that develops drugs for the treatment of newly diagnosed Parkinson's disease. IRLAB Therapeutics AB (publ) was incorporated in 2013 and is based in Gothenburg, Sweden.
Technical Analysis
Isofol Medical AB
―
Xintela AB
―
Elicera Therapeutics AB
―
Active Biotech AB
―
Initiator Pharma A/S
―